• Biology of Blood and Marrow Transplantation, the official publication of the American Society
for Transplantation and Cellular Therapy, publishes three peer-reviewed articles detailing
results from three separate trials of remestemcel-L in children and adults with acute graft
versus host disease
• Publications highlight consistent benefits seen across all three trials in patients with greatest
levels of inflammation and the most severe grades of the disease
• Trial results underpin Mesoblast’s Biologics License Application to seek approval of its product
candidate RYONCIL™ (remestemcel-L) for pediatric steroid-refractory acute graft versus host
disease (GVHD), which has been accepted for priority review by the United States Food and
Drug Administration (FDA)
• These outcomes also provide the rationale for use of remestemcel-L in other conditions
associated with severe inflammation and cytokine release, including COVID-19 infection
MSB Price at posting:
$3.72 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)